This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Gregory A. Poland, MD

JAMA. 1997;278(12):1022-1023.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

INFLUENZA IS a major killer of persons aged 65 years and older, particularly those who are frail or debilitated with chronic cardiac and/or pulmonary conditions, and results in 10 000 to 40 000 deaths each year in the United States. The economic cost is considerable, with Medicare reimbursing hospitals $1 billion for excess hospitalizations during the 1989 flu season¹ and an overall societal cost in excess of $10 billion.² To prevent illness and death, there has been a sustained and ongoing campaign to enhance the annual delivery of influenza vaccine to persons aged 65 years and older. For this reason, public concerns regarding "recalled" vaccine may negatively affect the success of these campaigns.

Three times during November 1996, Parke-Davis voluntarily recalled 11 lots of influenza vaccine (Fluogen, lots 00176P, 00276P, 00576P, 00586P, 00676P, 00686P, 00786P, 00886P, 00966P, 00986P, and 01066P). Based on information available, neither the Centers for . . . [Full Text PDF of this Article]

Author Affiliations
From the Mayo Vaccine Research Group, Mayo Clinic, Rochester, Minn.

Footnotes
Reprints: Gregory A. Poland, MD, Mayo Vaccine Research Group, Mayo Clinic, 601 B Guggenheim Bldg, 200 First St SW, Rochester, MN 55905.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?